Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.71 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.71 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649038 | 0.88 | GRM5 (0.56) | GRM5GRM1TRPV1PDE10APDK4 | |
| SCHEMBL4001532 | 0.87 | GRM5 (0.63) | GRM5GRM1PDE10APDK4TNK2 | |
| SCHEMBL31306939 | 0.87 | GRM5 (0.61) | GRM5GRM1PDE10APDK4TNK2 | |
| SCHEMBL1458617 | 0.87 | GRM5 (0.63) | GRM5GRM1TRPV1PDE10APDK4 | |
| SCHEMBL73964 | 0.86 | GRM5 (0.60) | GRM5GRM1PDE10APDK4TNK2 | |
| SCHEMBL4000426 | 0.86 | GRM5 (0.60) | GRM5GRM1TRPV1PDE10APDK4 | |
| SCHEMBL15941818 | 0.85 | GRM5 (0.59) | GRM5GRM1PDE10APDK4TNK2 | |
| SCHEMBL20955503 | 0.85 | GRM5 (0.59) | GRM5GRM1PDE10APDK4TNK2 | |
| SCHEMBL30676170 | 0.84 | GRM5 (0.61) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL2631187 | 0.84 | GRM5 (0.61) | GRM5GRM1PDE10APDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | GRM5 3710/4885GRM1 3072/4885TRPV1 1682/4885 |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | GRM5 202/4885GRM1 22/4885TRPV1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.